GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » Gross Profit

Reata Pharmaceuticals (Reata Pharmaceuticals) Gross Profit : $22.64 Mil (TTM As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals Gross Profit?

Reata Pharmaceuticals's gross profit for the three months ended in Jun. 2023 was $21.90 Mil. Reata Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $22.64 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Reata Pharmaceuticals's gross profit for the three months ended in Jun. 2023 was $21.90 Mil. Reata Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $22.75 Mil. Therefore, Reata Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 was 96.28%.

Reata Pharmaceuticals had a gross margin of 96.28% for the quarter that ended in Jun. 2023 => Durable competitive advantage

During the past 10 years, the highest Gross Margin % of Reata Pharmaceuticals was 96.40%. The lowest was -369.13%. And the median was -369.13%.


Reata Pharmaceuticals Gross Profit Historical Data

The historical data trend for Reata Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reata Pharmaceuticals Gross Profit Chart

Reata Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.59 -97.88 9.02 11.49 2.22

Reata Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.54 - 0.20 21.90

Competitive Comparison of Reata Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Reata Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reata Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's Gross Profit falls into.



Reata Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Reata Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=2.216 - 0
=2.22

Reata Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=22.746 - 0.846
=21.90

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.64 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Reata Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=21.90 / 22.746
=96.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Reata Pharmaceuticals  (NAS:RETA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Reata Pharmaceuticals had a gross margin of 96.28% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Reata Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
5320 Legacy Drive, Plano, TX, USA, 75024
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Executives
Steven Ryder director 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai director, 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni officer: EVP, Chief R&D Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand officer: SVP, Chief Accounting Officer 5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni officer: COO, CFO and President C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir officer: Chief Commercial Officer C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen officer: SVP, Global Regulatory Affairs C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr. director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley officer: See Remarks 5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John officer: See Remarks C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc. other: See footnotes 225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan officer: SVP, Chief Medical Officer 5320 LEGACY DRIVE, PLANO TX 75024

Reata Pharmaceuticals (Reata Pharmaceuticals) Headlines

From GuruFocus